Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Merck Serono’s Northeast Asian Development Zeros in on 4 Cancer Types: R&D Site Head
August 29, 2013
-
BUSINESS Takeda Initiates Overseas PIII Trial of Actos for Delaying the Onset of MCI Due to Alzheimer’s Disease
August 28, 2013
-
REGULATORY MHLW’s Economic Affairs Division Honing in on “4th Round” of Distribution Reform; Era of Bundling Won’t Return
August 27, 2013
-
ACADEMIA Osaka City University Slams Lead Investigators of Diovan Trials; They “Knew of His Novartis Affiliation”
August 26, 2013
-
REGULATORY Pharma Industry to Give Opinions at CSIMC Subcommittee in Sept., Stand against Health Ministry’s Plan to Cut Drug Prices
August 26, 2013
-
REGULATORY MHLW Proposes Plan to Downwardly Revise NHI Prices of Combination Drugs and Drugs Obtained as a Result of Optical Resolution of Racemic Bodies
August 23, 2013
-
BUSINESS Patent Cliff Hits Major Global Drug Makers, Weak Yen Weighs on Japan Sales
August 22, 2013
-
BUSINESS Increasing Awareness of Biosimilars to Establish Them as a New Category; Companies Forming Alliances to Build Development and Marketing System
August 21, 2013
-
BUSINESS ASKA to Roll Out Generics of Takeda Product for 1st Time
August 20, 2013
-
BUSINESS Diovan Generics Developed as AGs, “No Comment” on December Listing: Sandoz
August 20, 2013
-
ACADEMIA Health Ministry’s Diovan Committee Should Question Bosses of Ex-Novartis Employee Too, Says Key Member
August 19, 2013
-
BUSINESS Sandoz Gets Approval for Diovan Generics; AGs Likely to Hit Market 6 Months before Rivals
August 16, 2013
-
ACADEMIA British Journal The Lancet Begins Process of Retracting JIKEI Heart Study
August 16, 2013
-
REGULATORY 3 Ex-Officials of MHLW, NHO Affiliated with Novartis in 2010, Govt Says
August 15, 2013
-
REGULATORY PAFSC 2nd Committee to Review GSK’s Combination Asthma Drug on Aug. 26
August 14, 2013
-
REGULATORY EAD Director Visits 5 Hospital HQ to Urge Early Price Settlements, Greeted with Mixed Enthusiasm
August 13, 2013
-
REGULATORY 41,254 ADR Reports Received from Marketing Authorization Holders in FY2012: MHLW
August 13, 2013
-
BUSINESS Payments to Healthcare Professionals by 10 Drug Makers Top 150 Billion Yen
August 13, 2013
-
REGULATORY MHLW Diovan Committee: 3 More Universities Give 1st Probe Updates, SMART Data Rapped “Sloppy”
August 12, 2013
-
BUSINESS AZ’s Exenatide Promotion to Break Free from Weight-Loss Image of GLP-1 Receptor Agonists
August 9, 2013
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…